Revolution Medicines initiated at Morgan Stanley with overweight rating
Morgan Stanley initiated Revolution Medicines (NASDAQ: RVMD) with an overweight rating. The firm set a $255 price target, citing the company’s pipeline of RAS(“ON”) inhibitors.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.